Brief: Eliem Therapeutics - Current Cash, Cash Equivalents Expected To Fund Operations Through At Least 2023

Climb Bio

16/05/2022 11:16

May 16 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS - CURRENT CASH, CASH EQUIVALENTS & SHORT- AND LONG-TERM
MARKETABLE SECURITIES ARE EXPECTED TO FUND OPERATIONS THROUGH AT LEAST 2023
    * ELIEM THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.50

Source text for Eikon:  ID:nGNX2mWQmf 
Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;))